The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

Inclusion Criteria: * Patients must have a diagnosis of one of the following histologic types according to the WHO classification: * Angioimmunoblastic T-cell lymphoma * Extranodal NK/T-cell lymphoma,nasal type * Enteropathy-type T-cell lymphoma * Hepatosplenic gamma-delta T-cell lymphoma * Subcutaneous panniculitis-like T-cell lymphoma * Anaplastic large-cell lymphoma,T/null cell,primary systemic type * Peripheral T-cell lymphoma,not otherwise characterized * Newly diagnosed,age 15-65 years. * Complete work up for baseline evaluation and measurement (Appendix B) * Patient's free written inform consent. Exclusion Criteria: * Patients with a known hypersensitivity to murine proteins or to any component of alemtuzumab. * Patients who have received prior antilymphoma treatment with chemotherapy or radiotherapy * Patients with poor performance status (PS;ECOG criteria of 3-4)(Appendix C). * Serologic evidence of HCV and HCV RNA of chronic hepatitis. * Serologic evidence of HBV and HBV RNA of chronic hepatitis. * Patients with history of impaired cardiac status or myocardial infarction. * Patients with serum creatinine \>= 1.8 mg/dl,bilirubin \>= 1.5 times upper limit of normal range,SGOT or SGPT \>= 3 times upper limit of normal range, unless due to tumor involvement. * Patients with active uncontrolled infection,active non-malignant gastric or duodenal ulcer, uncontrolled diabetes mellitus or other severe medical conditions which would preclude aggressive cytotoxic chemotherapy. * Active secondary malignancy. * Pregnant or lactating women. * Serious medical or psychiatric illness which prevent informed consent. * Patients who are likely to lost to follow up (eg, unwilling or difficult to return,cannot be contacted).